Most patients with type 2 diabetes and chronic kidney disease should be managed with SGLT-2 inhibitors as first-line therapy in addition to lifestyle interventions, according to new guidance.

International researchers, including Australian endocrinologist Professor Sophia Zoungas, also advise renin–angiotensin–aldosterone system (RAAS) blockade “at maximum tolerated dose” in those with comorbid hypertension and albuminuria.